Format
Sort by

Send to:

Choose Destination

Results: 4

1.

Effect of erythropoiesis-stimulating agents on hemoglobin level, fatigue and hospitalization rate in renal palliative care patients.

Chan KY, Li CW, Wong H, Yip T, Sham MK, Cheng HW, Teo KC, Kwok WC, Chan TM.

Int Urol Nephrol. 2014 Mar;46(3):653-7. doi: 10.1007/s11255-014-0661-x. Epub 2014 Feb 14.

PMID:
24526333
2.

Dialysis patients treated with Epoetin alfa show improved anemia symptoms: A new analysis of the Canadian Erythropoietin Study Group trial.

Keown PA, Churchill DN, Poulin-Costello M, Lei L, Gantotti S, Agodoa I, Gitlin M, Gandra SR, Mayne TJ.

Hemodial Int. 2010 Apr;14(2):168-73. doi: 10.1111/j.1542-4758.2009.00422.x. Epub 2010 Mar 24.

PMID:
20345390
3.

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators.

N Engl J Med. 2009 Nov 19;361(21):2019-32. doi: 10.1056/NEJMoa0907845. Epub 2009 Oct 30.

4.

The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron.

Silverberg DS, Wexler D, Blum M, Tchebiner JZ, Sheps D, Keren G, Schwartz D, Baruch R, Yachnin T, Shaked M, Schwartz I, Steinbruch S, Iaina A.

Nephrol Dial Transplant. 2003 Jan;18(1):141-6.

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk